Christopher F Soares

US Patent:

8076288, Dec 13, 2011

Filed:

Aug 17, 2005

Appl. No.:

11/206903

Inventors:

Odile Esther Levy - San Diego CA, US
Michael R. Hanley - Corte Madera CA, US
Carolyn M. Jodka - Encinitas CA, US
Diana Y. Lewis - San Diego CA, US
Christopher J. Soares - La Jolla CA, US
Soumitra S. Ghosh - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
David G. Parkes - Del Mar CA, US
Christine M. Mack - San Diego CA, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 38/00
A61K 38/26

US Classification:

514 72, 514 68

Abstract:

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

US Patent:

8114958, Feb 14, 2012

Filed:

Feb 11, 2005

Appl. No.:

10/589054

Inventors:

Christopher J. Soares - La Jolla CA, US
Michael R. Hanley - Corte Madera CA, US
Diana Y. Lewis - San Diego CA, US
David Geoffrey Parkes - Del Mar CA, US
Carolyn M. Jodka - Encinitas CA, US
Kathryn S. Prickett - Foster City CA, US
Soumitra S. Ghosh - San Diego CA, US
Christine Marie Mack - San Diego CA, US
Qing Lin - Getzville NY, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07K 19/00
C07K 14/435
A61K 38/16
A61P 3/04

US Classification:

530307, 530324, 514 49, 514 119, 514909, 536 234

Abstract:

The present invention relates to obesity related polypeptides (ORPs), related nucleic acids, expression constructs, host cells, and processes production of the obesity related polypeptides. The ORPs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.

US Patent:

8263545, Sep 11, 2012

Filed:

Aug 17, 2007

Appl. No.:

11/840921

Inventors:

Odile Esther Levy - San Diego CA, US
Alain D. Baron - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Mary Erickson - San Diego CA, US
Soumitra S. Ghosh - San Diego CA, US
Michael R. Hanley - San Diego CA, US
Samuel Janssen - San Diego CA, US
Carolyn M. Jodka - San Diego CA, US
Diana Y. Lewis - San Diego CA, US
Christine M. Mack - San Diego CA, US
David G. Parkes - San Diego CA, US
Richard A. Pittner - San Diego CA, US
Christopher J. Soares - San Diego CA, US
Ved Srivastava - San Diego CA, US
Andrew A. Young - San Diego CA, US
Thao Le - San Diego CA, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 38/00
A61P 3/10

US Classification:

514 11, 514 68, 514 117

Abstract:

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

US Patent:

8404637, Mar 26, 2013

Filed:

Feb 10, 2006

Appl. No.:

11/816095

Inventors:

Odile Esther Levy - San Diego CA, US
Alain D. Baron - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Mary Erickson - San Diego CA, US
Soumitra S. Ghosh - San Diego CA, US
Michael R. Hanley - San Diego CA, US
Samuel Janssen - San Diego CA, US
Carolyn M. Jodka - San Diego CA, US
Diana Y. Lewis - San Diego CA, US
Christine M. Mack - San Diego CA, US
David G. Parkes - San Diego CA, US
Richard A. Pittner - San Diego CA, US
Christopher J. Soares - San Diego CA, US
Ved Srivastava - San Diego CA, US
Andrew A. Young - San Diego CA, US

Assignee:

Amylin Pharmaceuticals, LLC - San Diego CA

International Classification:

A61K 38/00
A61P 3/10

US Classification:

514 72, 514 68

Abstract:

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

US Patent:

8497240, Jul 30, 2013

Filed:

Aug 17, 2007

Appl. No.:

12/377856

Inventors:

Odile Esther Levy - San Diego CA, US
Alain D. Baron - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Mary Erickson - San Diego CA, US
Soumitra S. Ghosh - San Diego CA, US
Michael R. Hanley - Corte Madera CA, US
Samuel Janssen - San Marcos CA, US
Carolyn M. Jodka - Encinitas CA, US
Diana Y. Lewis - San Diego CA, US
Christine M. Mack - San Diego CA, US
David G. Parkes - Del Mar CA, US
Richard A. Pittner - Palo Alto CA, US
Christopher J. Soares - La Jolla CA, US
Ved Srivastava - Cary NC, US
Andrew A. Young - Chapel Hill NC, US
Thao Le - Carlsbad CA, US

Assignee:

Amylin Pharmaceuticals, LLC - San Diego CA
AstraZeneca Pharmaceuticals LP - Wilmington DE

International Classification:

A61K 38/00
A61K 38/16
A61K 38/26

US Classification:

514 69, 514 213, 514 72, 514 117, 530324, 530308

Abstract:

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

US Patent:

8598120, Dec 3, 2013

Filed:

Feb 1, 2012

Appl. No.:

13/364250

Inventors:

Christopher J. Soares - La Jolla CA, US
Michael R. Hanley - Corte Madera CA, US
Diana Y. Lewis - San Diego CA, US
David G. Parkes - Del Mar CA, US
Carolyn M. Jodka - Encinitas CA, US
Kathryn S. Prickett - Foster City CA, US
Soumitra S. Ghosh - San Diego CA, US
Christine M. Mack - San Diego CA, US
Qing Lin - Getzville NY, US

Assignee:

Amylin Pharmaceuticals, LLC - San Diego CA
AstraZeneca Pharmaceuticals LP - Wilmington DE

International Classification:

A61K 38/16
A61P 3/04
A61P 5/22
C07K 14/435
C07K 19/00

US Classification:

514 119, 435 697, 514 49, 514909, 530307, 530329, 536 234, 930 60

Abstract:

The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.

US Patent:

8598314, Dec 3, 2013

Filed:

Sep 26, 2008

Appl. No.:

12/680539

Inventors:

Soumitra S. Ghosh - San Diego CA, US
Josue Alfaro-Lopez - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Odile Esther Levy - San Diego CA, US
Qing Lin - San Diego CA, US
Christopher J. Soares - San Diego CA, US

Assignee:

Amylin Pharmaceuticals, LLC - San Diego CA
AstraZeneca Pharmaceuticals LP - Wilmington DE

International Classification:

A61K 38/00
C07K 5/00
C07K 7/00
C07K 16/00
C07K 17/00

US Classification:

530324, 530325, 530326

Abstract:

Peptide-peptidase inhibitor conjugate molecules and methods of manufacture thereof are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.

US Patent:

20060094652, May 4, 2006

Filed:

Feb 11, 2005

Appl. No.:

11/055093

Inventors:

Odile Levy - San Diego CA, US
Michael Hanley - Corte Madera CA, US
Carolyn Jodka - Encinitas CA, US
Diana Lewis - San Diego CA, US
Christopher Soares - La Jolla CA, US
Soumitra Ghosh - San Diego CA, US
Lawrence D'Souza - San Diego CA, US
David Parkes - Del Mar CA, US
Christine Mack - San Diego CA, US

International Classification:

A61K 38/22
A61K 38/23
A61K 38/26

US Classification:

514012000, 530399000, 530307000

Abstract:

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.